Agios ClarIDHy

The ClarIDHy clinical trial is testing the safety and efficacy of an investigational medication, AG-120, in eligible patients with IDH1-mutated advanced cholangiocarcinoma.

AG-120: Investigational medication for IDH1-mutated advanced cholangiocarcinoma

AG-120, developed by Agios, is a targeted therapy that targets cancer cells with a mutation in a gene called IDH1. Among patients with cholangiocarcinoma, 13%-15% may have an IDH1 mutation in their tumour.

March 2018: This international trial is now open and recruiting at the following centres in the UK:

The Christie, Manchester – Professor Juan Valle
Direct e-mail:
PA: Lindsey Duncan:
Tel 0161 446 8106
Fax 0161 446 3468
e-mail: lindsey.duncan@christie.nhs

UCL, London – Professor John Bridgewater
Professor John Bridgewater’s contact details:
Tel: 020 3447 9093
Fax: 020 3447 9055

Royal Free London NHS Foundation Trust – Dr Roopinder Gillmore,

Agios Pharmaceuticals, Inc identifier: NCT02989857

For more information on this trial go to:


The following European sites are also currently recruiting:


  • Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer (Marc Pracht)
  • Hopital Jean Minjoz (Christophe Borg)
  • Institut Gustave Roussy Institut Bergonie Centre Regional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest (Marianne Fonck)
  • Institut Gustave Roussy (David Malka)


  • Hospital Universitario Vall d’Hebron – PPDS (Teresa Macarulla Mercade)
  • Hospital Universitario 12 de Octubre (Jorge Adeva Alfonso)
  • Hospital Universitario HM Sanchinarro – CIOCC (Antonio Cubillo Gracián)
  • Hospital General Universitario Gregorio Marañon (Andres Muñoz)
  • Hospital Universitario Marques de Valdecilla (Fernando Rivera)


  • Ospedale San Raffaele S.r.l. – PPDS (Luca Gianni)

Sites are also currently recruiting in the USA and South Korea.

Back to previous page